Zacks Investment Research downgraded shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) from a buy rating to a hold rating in a research report report published on Wednesday.

According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “

Separately, Cantor Fitzgerald cut Sunesis Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, December 28th.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/zacks-investment-research-lowers-sunesis-pharmaceuticals-inc-snss-to-hold.html

Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at 4.23 on Wednesday. The company’s market capitalization is $88.51 million. The company has a 50 day moving average of $4.15 and a 200 day moving average of $4.11. Sunesis Pharmaceuticals has a 1-year low of $2.63 and a 1-year high of $6.30.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. Sunesis Pharmaceuticals had a negative net margin of 1,623.12% and a negative return on equity of 806.43%. The company earned $0.68 million during the quarter, compared to the consensus estimate of $0.60 million. During the same quarter in the previous year, the company earned ($0.91) earnings per share. The business’s revenue was up 1.5% on a year-over-year basis. On average, analysts predict that Sunesis Pharmaceuticals will post ($2.48) earnings per share for the current fiscal year.

Your IP Address:

A number of institutional investors have recently modified their holdings of SNSS. Renaissance Technologies LLC raised its position in shares of Sunesis Pharmaceuticals by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 110,581 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 16,000 shares during the period. Vivo Capital LLC acquired a new position in shares of Sunesis Pharmaceuticals during the fourth quarter valued at about $1,810,000. Boxer Capital LLC acquired a new position in shares of Sunesis Pharmaceuticals during the fourth quarter valued at about $1,901,000. Baker BROS. Advisors LP acquired a new position in shares of Sunesis Pharmaceuticals during the third quarter valued at about $3,241,000. Finally, Great Point Partners LLC acquired a new position in shares of Sunesis Pharmaceuticals during the third quarter valued at about $4,648,000. 34.30% of the stock is currently owned by hedge funds and other institutional investors.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

5 Day Chart for NASDAQ:SNSS

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.